Supha Pharmachem (BOM:539561) Piotroski F-Score: 5 (As of Jul. 07, 2026) — Near Median


BOM:539561 Supha Pharmachem Ltd BOM:539561
60 GF Score
Price ₹0.34
GF Value ₹1.53
Valuation Possible Value Trap
! 12 Warning Signs
View Full Analysis

What is Supha Pharmachem Piotroski F-Score?

Supha Pharmachem BOM:539561 +3.03% 60 Piotroski F-Score is 5 as of Jul. 07, 2026, which is at its 10-year median of 5.00. GuruFocus rates BOM:539561 with a GF Score™ of 60/100 and a GF Value™ of ₹1.53 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 981 Drug Manufacturers companies, Supha Pharmachem ranks better than 61.26% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Supha Pharmachem has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Supha Pharmachem's Piotroski F-Score or its related term are showing as below:

BOM:539561' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 5

During the past 11 years, the highest Piotroski F-Score of Supha Pharmachem was 7. The lowest was 3. And the median was 5.

Supha Pharmachem  (BOM:539561) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Supha Pharmachem Piotroski F-Score Related Terms


Supha Pharmachem Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Supha Pharmachem's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supha Pharmachem Piotroski F-Score Chart

Supha Pharmachem Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 5.00 6.00 6.00 5.00

Supha Pharmachem Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 5.00 0.00 0.00

BOM:539561 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supha Pharmachem Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Supha Pharmachem's Piotroski F-Score falls into.


BOM:539561
60GF Score
Supha Pharmachem Ltd BOM:539561
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar25) TTM:Last Year (Mar24) TTM:
Net Income was ₹21 Mil.
Cash Flow from Operations was ₹-11,444 Mil.
Revenue was ₹4,053 Mil.
Gross Profit was ₹71 Mil.
Average Total Assets from the begining of this year (Mar24)
to the end of this year (Mar25) was (19479.236 + 17203.49) / 2 = ₹18341.363 Mil.
Total Assets at the begining of this year (Mar24) was ₹19,479 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹17,203 Mil.
Total Current Liabilities was ₹16,765 Mil.
Net Income was ₹327 Mil.

Revenue was ₹40,417 Mil.
Gross Profit was ₹403 Mil.
Average Total Assets from the begining of last year (Mar23)
to the end of last year (Mar24) was (11542.227 + 19479.236) / 2 = ₹15510.7315 Mil.
Total Assets at the begining of last year (Mar23) was ₹11,542 Mil.
Long-Term Debt & Capital Lease Obligation was ₹0 Mil.
Total Current Assets was ₹19,478 Mil.
Total Current Liabilities was ₹19,050 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Supha Pharmachem's current Net Income (TTM) was 21. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Supha Pharmachem's current Cash Flow from Operations (TTM) was -11,444. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar24)
=21.294/19479.236
=0.00109316

ROA (Last Year)=Net Income/Total Assets (Mar23)
=327.302/11542.227
=0.02835692

Supha Pharmachem's return on assets of this year was 0.00109316. Supha Pharmachem's return on assets of last year was 0.02835692. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Supha Pharmachem's current Net Income (TTM) was 21. Supha Pharmachem's current Cash Flow from Operations (TTM) was -11,444. ==> -11,444 <= 21 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/18341.363
=0

Gearing (Last Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=0/15510.7315
=0

Supha Pharmachem's gearing of this year was 0. Supha Pharmachem's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar25)=Total Current Assets/Total Current Liabilities
=17203.049/16764.58
=1.02615449

Current Ratio (Last Year: Mar24)=Total Current Assets/Total Current Liabilities
=19478.499/19049.658
=1.02251174

Supha Pharmachem's current ratio of this year was 1.02615449. Supha Pharmachem's current ratio of last year was 1.02251174. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Supha Pharmachem's number of shares in issue this year was 577.654. Supha Pharmachem's number of shares in issue last year was 577.654. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=71.16/4052.511
=0.01755948

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=403.314/40417.067
=0.0099788

Supha Pharmachem's gross margin of this year was 0.01755948. Supha Pharmachem's gross margin of last year was 0.0099788. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar24)
=4052.511/19479.236
=0.2080426

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar23)
=40417.067/11542.227
=3.50166974

Supha Pharmachem's asset turnover of this year was 0.2080426. Supha Pharmachem's asset turnover of last year was 3.50166974. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+0+0+0+1+1+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Supha Pharmachem has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Supha Pharmachem (BOM:539561) has a Piotroski F-Score of 5 as of Jul. 07, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Supha Pharmachem and its competitors. This is near median its historical median of 5.00. Over the past decade, Supha Pharmachem's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Supha Pharmachem ranks #380 out of 981 companies in the Drug Manufacturers industry, placing it in the top 38.7%.
Is Supha Pharmachem's Piotroski F-Score too high?
Supha Pharmachem's current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Supha Pharmachem's value of 5 is 0% at this industry median. Based on the distribution chart, Supha Pharmachem ranks #380 out of 981 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Supha Pharmachem has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #380 out of 981 companies for Piotroski F-Score. This puts Supha Pharmachem in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Supha Pharmachem's value of 5 is 0% at this benchmark. Historically, Supha Pharmachem's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Supha Pharmachem has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supha Pharmachem's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Supha Pharmachem and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supha Pharmachem's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.53, compared to a current price of ₹0.34 — trading 77.8% below its estimated fair value. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Supha Pharmachem's overall GF Score™ is 60/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current Piotroski F-Score is 5 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supha Pharmachem (BOM:539561) Overvalued in 2026?

Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued. The current stock price of ₹0.34 is trading 77.8% below its estimated GF Value™ of ₹1.53. GuruFocus considers Supha Pharmachem to be Possible Value Trap.

Key valuation signals for BOM:539561:

  • Piotroski F-Score: 5 (near median its 10-year median of 5.00)
  • GF Value™: ₹1.53 vs. price of ₹0.34 (77.8% below fair value)
  • GF Score™: 60/100 with 12 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#380 of 981)

No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supha Pharmachem Business Description

Address Saugbaug Road, Office No. 9, Behind Ravi Vihar Hotel, K Raheja Prime, Marol Industrial Estate, Andheri (East), Mumbai, MH, IND, 400059
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
60GF Score

Get the complete analysis for BOM:539561

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹0.34
Price
₹1.53
GF Value